AlenCiken

New data independently confirms and extends laboratory findings

NASDAQ:ATHE   Alterity Therapeutics Limited
New data independently confirms and extends laboratory findings and expands safety profile of ATH434

new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for presentation at the 2020 International Congress of Parkinson's Disease and Movement Disorders (MDS 2020) and the American Neurological Association's 2020 Annual Meeting (ANA 2020).


both conferences will be held in a virtual format with MDS 2020 being held 12-16th September, and ANA 2020 to be held 4-9th October.

finance.yahoo.c...-013300738.html?guce_refer...



Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.